Pott, Christiane
Sehn, Laurie H.
Belada, David
Gribben, John
Hoster, Eva
Kahl, Brad
Kehden, Britta
Nicolas-Virelizier, Emmanuelle
Spielewoy, Nathalie
Fingerle-Rowson, Guenter
Harbron, Chris
Mundt, Kirsten
Wassner-Fritsch, Elisabeth
Cheson, Bruce D.
Funding for this research was provided by:
F. Hoffmann-La Roche Ltd/Genentech Inc.
Article History
Received: 25 March 2019
Revised: 25 June 2019
Accepted: 15 July 2019
First Online: 28 August 2019
Compliance with ethical standards
:
: CP reports research funding and advisory board membership for F. Hoffmann-La Roche Ltd, and advisory board membership for Janssen. DB reports research funding, advisory board membership, and consultancy fees for F. Hoffmann-La Roche Ltd, Gilead Sciences, and Janssen-Cilag. ND, GFR, CH, EWF, and KM are employees of and own stock in F. Hoffmann-La Roche Ltd. JG reports advisory board membership and research funding from Roche/Genentech, advisory board membership for Abbvie, and speakers’ fees, research funding and advisory board membership for Janssen, Acerta, Pharmacyclics, and TG Therapeutics. EH reports travel support from Roche Pharma AG. B Kahl reports advisory board membership for F. Hoffmann-La Roche Ltd. B Kehden and ENV report no conflict of interest. LHS reports consultancy fees for Roche/Genentech, Amgen, Lundbeck, Seattle Genetics, Janssen, Celgene, Abbvie, and TG Therapeutics. BDC reports advisory board membership for Roche/Genentech, Abbvie, and Acerta and research funding to his institution from F. Hoffmann-La Roche Ltd/Genentech Inc.